Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Only a pregnancy fetal-toxicity/discontinue message is label-supported, but the provided AI-generated list contains many pricing/competition/coupon/country-patent claims and general “safe/effective” statements that are not supported by the FDA prescribing information excerpts provided, making overall alignment partial.
Category Scores
Accurate Statements
When pregnancy is detected, Diovan (valsartan) should be discontinued as soon as possible (fetal harm / fetal toxicity).
Supported by label language in Section 5.1: “When pregnancy is detected, discontinue Diovan as soon as possible [see Use in Specific Populations (8.1)].” and Section 8.1: “consider alternative drug treatment and discontinue Diovan as soon as possible.”
Unsupported Statements
Valsartan 160 mg pricing can vary by manufacturer, pharmacy, insurance coverage, and whether the product is generic or brand-name.
No pricing/insurance/coupon statements appear in the supplied prescribing information excerpts.
Specific formulation (e.g., immediate-release) can affect the cost of Valsartan 160 mg.
No formulation-to-cost linkage is provided in the supplied label excerpts.
The number of tablets in a prescription can affect the cost of Valsartan 160 mg.
No label support in provided excerpts.
Generic versions of Valsartan are generally less expensive than brand-name due to increased market competition after patent expirations.
No support in provided label excerpts.
Insurance plans significantly affect Valsartan 160 mg cost, including differences in copays and coverage tiers.
No support in provided label excerpts.
Discount programs and pharmacy coupons can reduce the cost of Valsartan 160 mg.
No support in provided label excerpts.
Comparing prices across pharmacies (including brick-and-mortar and online) can help find the most affordable Valsartan 160 mg.
Not present in supplied prescribing information excerpts.
Some pharmacies offer lower prices for longer supply (e.g., 90-day supply vs 30-day supply).
No support in provided label excerpts.
Patent expiry dates for Valsartan are crucial for understanding availability of generic versions and their impact on pricing.
Not addressed in provided prescribing information excerpts.
Valsartan patent expiration dates can vary by country and by specific patent.
Not addressed in provided prescribing information excerpts.
When primary patents expire, generic manufacturers can enter the market, typically reducing overall drug costs.
Not addressed in provided prescribing information excerpts.
Valsartan is generally considered safe and effective.
No such general efficacy/safety conclusion is supported by the provided label excerpts.
Valsartan may cause kidney problems.
Kidney-related effects are not described in the supplied fetal-toxicity excerpts; may be present elsewhere in the full label but is not supported by the provided excerpts.
Valsartan may cause elevated potassium levels.
Hyperkalemia is mentioned in the supplied pregnancy monitoring text for neonates (“hyperkalemia”), but the blanket statement is broader than the excerpted pregnancy-neonate context and is not fully supported as written by the provided excerpts.
Valsartan may cause angioedema, which is described as rare but severe.
Angioedema is not described in the supplied fetal toxicity/pregnancy excerpts.
If Valsartan is not suitable, alternative ARBs or other blood pressure medication classes (ACE inhibitors, calcium channel blockers, diuretics) may be prescribed.
The label excerpt supports considering alternative drug treatment when pregnancy is detected, but does not support this broad alternative-class guidance for general “not suitable” scenarios.
Generic Valsartan is bioequivalent to brand-name Valsartan.
No generic-bioequivalence statements are included in the provided label excerpts.
Generic Valsartan contains the same active ingredient, in the same dosage form and strength, and is intended to have the same therapeutic effect.
Not addressed in the provided label excerpts.
The primary differences between generic and brand-name Valsartan are typically inactive ingredients and appearance, as well as price.
Not addressed in the provided label excerpts.
Generic medications are subject to FDA regulations to meet the same quality and safety standards as brand-name drugs.
Not addressed in the provided label excerpts.
Insurance copays for Valsartan 160 mg can vary significantly.
Not addressed in the provided label excerpts.
Valsartan 160 mg copay variation is influenced by the patient's insurance plan, deductible status, and whether the medication is on a preferred or non-preferred tier.
Not addressed in the provided label excerpts.
Contradictions
Important Omissions
The pregnancy discontinuation statement is the only label-supported fetal-toxicity action; the provided AI list does not explicitly include the label’s trimester-specific context (second and third trimesters) and the specific fetal/neonatal adverse reaction spectrum (e.g., oligohydramnios-related findings such as fetal lung hypoplasia and skeletal deformations; and neonatal adverse effects including anuria/renal failure/hypotension/death) that would be material to accurately conveying the fetal toxicity warning.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Some key pregnancy/fetal-toxicity guidance (discontinue as soon as pregnancy detected) is supported, but many other statements are unsupported by the provided label excerpts and lack the specific trimester-specific fetal harm and detailed fetal/neonatal adverse reaction information present in the prescribing information.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Mostly Aligned
Primary Issue
Large portion of the AI-generated content is not supported by the provided FDA label excerpts (pricing/insurance/patent/general safety/other adverse effects/alternative-class guidance).
Suggested Improvement
Limit claims to what is present in the prescribing information excerpts; for fetal toxicity, include the label’s trimester-specific risk, oligohydramnios-associated findings, and the exact discontinuation instruction wording from Sections 5.1 and 8.1.